STK11 and prostate cancer: While STK11 deletion or inactivating mutations are frequent in lung cancer (occurring in up to 50% of patients) [208], STK11 mutations are rare in prostate cancer (0.2% incidence, Tables S1–S3) and the frequency of STK11 deep deletion is also comparatively low (0–3.4% incidence, Tables S1–S3).